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A B S T R A C T   
The development of cell microencapsulation systems began several decades ago. However, today few systems 
have been tested in clinical trials. For this reason, in the last years, researchers have directed efforts towards 
trying to solve some of the key aspects that still limit efficacy and biosafety, the two major criteria that must be 
satisfied to reach the clinical practice. Regarding the efficacy, which is closely related to biocompatibility, 
substantial improvements have been made, such as the purification or chemical modification of the alginates that 
normally form the microspheres. Each of the components that make up the microcapsules has been carefully 
selected to avoid toxicities that can damage the encapsulated cells or generate an immune response leading to 
pericapsular fibrosis. As for the biosafety, researchers have developed biological circuits capable of actively 
responding to the needs of the patients to precisely and accurately release the demanded drug dose. Furthermore, 
the structure of the devices has been subject of study to adequately protect the encapsulated cells and prevent 
their spread in the body. The objective of this review is to describe the latest advances made by scientist to 
improve the efficacy and biosafety of cell microencapsulation systems for sustained drug delivery, also high-
lighting those points that still need to be optimized.   
1. Introduction 
For more than four decades, different materials, both of natural and 
synthetic origin, have been used to manufacture sustained drug delivery 
systems. Among them, we find those that allow the sustained release of 
encapsulated growth factors, proteins or drugs; but also others, of 
greater complexity, that are capable of immobilizing and protecting 
living cells, selectively isolating them from their environment while they 
secrete the therapeutic molecules of interest. Cell encapsulation systems 
have shown wide applicability in pathologies with very diverse char-
acteristics, such as diabetes mellitus (DM), anemia, hemophilia B or 
pathologies of the central nervous system (CNS), among others [1]. They 
are especially convenient for pathologies in which maintaining a strict 
control over the release of the therapeutic molecule is essential. 
Cell encapsulation can be classified based on the size of the system. 
On the one hand, we find cell macroencapsulation systems, in which the 
cells are immobilized in relatively large diffusion chambers, with 
semipermeable properties. They can have different shapes, such as discs, 
flat sheets or hollow fibers. The application of cell macroencapsulation 
devices have shown very good results in vivo demonstrating their un-
deniable therapeutic potential. However, macrocapsules are character-
ized by a relatively small surface/volume ratio, which is probably their 
worst disadvantage, since this implies the need for large amounts of 
nutrients and oxygen to achieve an adequate diffusion into the chamber 
and limits the amount of cells that can be encapsulated without creating 
necrotic nuclei in the innermost and inaccessible areas [2]. 
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Cell microencapsulation represents a very interesting alternative, 
greatly improving the surface/volume ratio and increasing the diffusion 
of nutrients and oxygen inside the capsules. Cell microencapsulation 
strategy is based on the immobilization of cells that produce therapeu-
tically relevant molecules in spherical particles between 100 and 1500 
μm in diameter, approximately. The particles are elaborated with 
biocompatible materials and usually surrounded by a semi-permeable 
polymeric membrane that prevents the passage of high molecular 
weight molecules — antibodies and other components of the immune 
system —, protecting these cells from the host's immune response and 
from the mechanical stress that may occur when the implant is placed in 
the selected tissue [3]. In addition, the microcapsule must exert a tight 
control over the bidirectional diffusion of molecules — entrance of nu-
trients and oxygen; and release of de novo synthesized therapeutic fac-
tors and metabolic subproducts —, and provide cells with a suitable 
environment to enhance and modulate their function. This technology 
also suppresses, or at least reduces, the chronic administration of 
immunosuppressive agents, thus avoiding some of the adverse events 
associated with organ and tissue transplantation. On the other hand, the 
constant improvements in imaging techniques and robotic surgery 
procedures allow the access to difficult to reach areas for implantation 
[4]. 
Today, the results obtained in the various clinical trials carried out to 
date, make clear the advantages and potential applications of this 
promising technology. However, there are still aspects that need to be 
improved so that cell microencapsulation systems can be applied 
routinely in clinical practice. For this reason, in the last years, re-
searchers have directed efforts towards trying to solve some of the key 
aspects that still limit efficacy and biosafety, the two major criteria that 
must be satisfied to reach the clinical practice. Those two concepts are 
closely related to each other and must be carefully defined and regulated 
due to their implications regarding patient well-being. The objective of 
this review is, therefore, to group and describe the extensive work car-
ried out with the aim to improve these criteria, emphasizing the points 
that still need to be optimized. 
2. Efficacy - biocompatibility 
When talking about efficacy of cell microencapsulation, biocom-
patibility is one of the most important aspects to be considered. It will 
determine implant’s viability, functionality and durability, becoming in 
many cases a limiting factor to succeed. The biocompatibility of the 
implant must be given in 2 directions (Fig. 1). From outside to inside, the 
materials used must protect the immobilized cells, avoiding direct 
toxicity or the blockage of nutrients and oxygen diffusion. From inside to 
outside, none of the system components — cells, biomaterials, cross-
linking agents, etc. — or procedures used must be toxic for the patient or 
elicit an immune response in the host. When this occurs, the foreign 
body reaction (Box 1) can eventually isolate the implant within a 
fibrotic capsule, thereby preventing the access of essential molecules 
and leading to graft failure. In addition, the biocompatibility must last 
over time, since live cell therapies are normally used for long-term 
treatments. In this sense, several experts in the field of cell encapsula-
tion have decided to define the term "biotolerability", considering it 
more appropriate than "biocompatibility" [5]. 
Despite the undeniable improvement occurred in recent decades, the 
biomaterials and cells that are used today continue to produce, to a 
greater or lesser extent, an inflammatory response by the host, so 
searching for suitable components remains a priority. The final perfor-
mance of the device will depend not only on the biomaterials and cells 
used, but also on the site of implant, the local application of immuno-
suppressive drugs, or even the size and shape of the implant. 
2.1. Biomaterials, crosslinkers and coatings 
2.1.1. Biomaterials and cross-linkers 
On the one hand, the elaborated devices must present a suitable 
structure, resistant to unwanted degradation that avoids contact be-
tween the encapsulated cells and the host immune system. Furthermore, 
the biomaterials must guide the processes of proliferation and differ-
entiation of encapsulated cells, enhancing their viability and function-
ality. On the other hand, the choice of all the materials must be made 
taking into account possible toxicities. The latter includes, in addition to 
the main materials, cross-linkers, physicochemical modifications and 
possible degradation byproducts. 
Today, the materials used include ceramics, plastics and various 
polymers, among others. The latter can be classified as natural (poly-
saccharides, polypeptides and polynucleotides) or synthetic. Among 
natural polymers, polysaccharides are the most used because they allow 
relatively smooth encapsulation processes that are compatible with cell 
viability. Examples of natural polymers are alginate, agarose, collagen, 
or cellulose. On the other hand, polyethylene glycol (PEG) continues to 
be the most widely used option among synthetic polymers, along with 
poly(lactic-co-glycolic acid) (PLGA) and polyvinyl alcohol (PVA) 
[11,12]. 
Among all the available polymers, alginate is by far the most widely 
Fig. 1. Factors that may compromise implant 
biocompatibility/biotolerability. Regarding the 
biomaterials and coatings used, factors such as the 
permeability of the microcapsule to pro- 
inflammatory molecules, the characteristics of the 
implant surface, the size and shape of the sphere or 
structural deficiencies can trigger an immune 
response against the capsules. The encapsulated cells 
can also release pro-inflammatory molecules or pro-
trude outside the implant. Futhermore, the charac-
teristics of the implant site should also be considered 
in detail when trying to improve the biocompati-
bility/biotolerability of the system.   
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used biomaterial in cell microencapsulation systems, due to its excellent 
biocompatibility and easy handling [13]. Alginate is a natural anionic 
polysaccharide that creates three-dimensional structures, going from sol 
to gel, when it reacts with divalent ions. It is made up of different pro-
portions of residues of β-D-manuronic acid (M) and α-L-guluronic acid 
(G) that create different structures according to the ratio of G and M. 
Determining and standardizing this proportion is essential since it has a 
great influence on some of alginate hydrogels properties, such as their 
biocompatibility, stability, mechanical resistance and permeability, 
among others [13]. In general, alginates with a higher proportion of G 
blocks are stiffer, compared to those with a higher proportion of M 
blocks that have better elastic properties, due to the greater affinity of 
guluronic acid for divalent ions, and these physical-mechanical differ-
ences affect the way the immune system reacts against the implant [14]. 
On the other hand, the purity degree of the alginate is directly related 
to its biocompatibility. Low purity alginates contain endotoxins, pro-
teins and polyphenols that reduce the biocompatibility of the implants 
and can damage the encapsulated cells [15]. Several commercial algi-
nates have been described to contain pathogen-associated molecular 
patterns (PAMPs). These are potent initiators of inflammatory responses 
[16] and produce the release of small proinflammatory cytokines — 
such as interleukin 1β (IL-1β), the tumor necrosis factor α (TNF-α) or 
interleukin 6 (IL-6) —, which can come into contact with the encapsu-
lated cells and cause damage. The most common endotoxin that can be 
found in alginate are lipopolysaccharides (LPS), which can bind to toll- 
like receptors 4 (TLR-4) [17], producing an inflammatory response 
mediated by a variety of cells of the immune system [18]. Therefore, in 
recent years, different purification methods have been developed in 
order to obtain ultra-pure alginates with less immunogenicity in vivo 
[19–22]. However, there is great variability between the procedures 
used in the different research groups and it is still necessary to improve 
the tools for the screening and elimination of these and other impurities, 
such as peptidoglycans and lipoteicoic acid [23–27]. 
In this sense, there are divided opinions on whether or not it will be 
possible to achieve an adequate and sufficient level of purification of the 
alginate — so that it becomes nearly inert to the immune system — or 
whether it will also be necessary to chemically modify its structure. 
Indeed, pericapsular fibrosis has been one of the major drawbacks in 
clinical studies carried out to date with alginate as the main material. 
However, the composition of the alginate and the variability between 
administration protocols, cell types or the concomitant use of different 
coating materials, among others, make the comparison complicated. 
In recent years, alginate purification protocols have been refined 
[27], while some groups have begun to include chemical modifications 
in the alginates [28,29]. A few years ago, Paredes-Juarez et al. created a 
platform that allows the identification of pattern recognition receptor 
(PRR) activating polymers, in order to identify contaminants in the 
biomaterials [16]. On the other hand, in a study carried out by Vegas et 
al., a combinatorial approach was used to generate a wide range of 
alginate variants with the aim of finding those that were able to decrease 
the foreign body response [28]. After a first selection, the most prom-
ising hydrogel spheres were evaluated in vivo, in rodents and non-human 
primates (cynomolgus macaques). Three triazole-containing analogues 
(Z2-Y12, Z1-Y15 and Z1-Y19) were identified, which significantly 
reduced the foreign body response, when compared to conventional 
SLG20 alginate spheres inhibiting macrophage recognition and fibrosis 
formation (Fig. 2). When implanted intraperitoneally into non-human 
primates (n = 3 each alginate variant), Z2-Y12, Z1-Y15 and Z1-Y19 
spheres with 1.5-mm diameters displayed substantially reduced 
fibrotic responses after 4 weeks compared to 1.5-mm SLG20 spheres. 
SLG20 spheres had more extensive immune macrophage and fibrosis- 
associated activated myofibroblast coverage, consistent with the 
visible fibrotic overgrowth seen in the phase contrast imaging. Z1-Y19 
spheres displayed more coverage by macrophage and myofibroblasts 
than either Z2-Y12 or Z1-Y15, but less compared to SLG20. Z2-Y12 and 
Z1-Y15 spheres had markedly lower levels of smooth muscle actin 
(SMA) protein, the major morphological characteristic of myofibro-
blasts, as compared to SLG20 spheres, but Z1-Y19 spheres did not, 
despite the lower average SMA measured. Hydroxyproline quantifica-
tion revealed lower collagen levels for all three lead formulations 
compared to SLG20. 
In an interesting and more recent study, Liu et al. proposed a group of 
zwitterionic sulfobetaine (SB) and carboxybetaine (CB) modifications of 
alginate (SB-SLG20 and CB-SLG20) to reduce cell accumulation and 
Box 1 
Foreign body reaction against biomaterials. 
Although the materials and therapeutic applications differ, the process by which the body produces rejection against implants has many points 
in common. This is known as "foreign body reaction" and consists of the following phases: 
Immediately after the implantation and depending on the characteristics of its surface —material, shape, roughness, electrostatic charge, etc. — 
and the injury caused during the surgical process, various host proteins — such as albumin, fibronectin or complement molecules — will start to 
adhere to the surface of the implant. This creates a chemoattractive gradient for the innate immune response [6]. Neutrophils are the first cell 
type present at the implant site and their function is to engulf the microorganism remains and dead cells. Neutrophils also secrete proteases, 
lysozymes, reactive species and other enzymes to eliminate any type of biodegradable material. At the same time, they secrete cytokines and 
other factors that cause the activation of macrophages (differentiated from the recruited monocytes), which will be the predominant cell type in 
the following phases of the foreign body response. This acute phase of the inflammatory reaction would end with a return to homeostasis if the 
material recognized as foreign disappears completely. 
On the contrary, if the host cannot destroy the implant, its continued presence can lead to a second phase of chronic inflammation. The 
“frustrated” macrophages start to fuse into multinucleated cells around the implant, giving rise to foreign-body giant cells [7]. At the molecular 
level, pro-inflammatory cytokines, such as IL-6, TNF-α, interleukin 4 (IL-4), and interleukin 13 (IL-13), have been reported to be overexpressed 
[8]. In this phase, there is a continuous presence of monocytes and lymphocytes and a constant activation of macrophages and neutrophils, 
which secrete enzymes and reactive species. At the same time, neovascularization phenomena are observed, with the appearance of functional 
capillaries. 
In the final phase, fibroblasts, activated by macrophages, deposit collagen fibers to form a dense and fibrous acellular capsule that isolates the 
implant from the surrounding tissue [9]. This prevents the passage of nutrients and oxygen, and eventually leads to compromising the viability 
of the encapsulated cells. 
In vivo the chronology varies depending on the organism, ranging from the appearance of fibrosis in just 7 days, in the case of mini-pigs, to 14 
days in rats [10].  
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Fig. 2. Modified hydrogels mitigate foreign body response in non-human primates. Z2-Y12, Z1-Y15 and Z1-Y19 alginate spheres significantly reduce fibrosis in 
cynomolgus macaques, while conventional SLG20 alginate spheres become fibrotic. a Phase contrast imaging of spheres retrieved after 4 weeks in the intraperitoneal 
space show less fibrosis on Z2-Y12, Z1-Y15 and Z1-Y19 spheres than on SLG20. Scale bars, 2,000 μm; n = 3. b Confocal imaging of retrieved spheres from a after 4 
weeks in the intraperitoneal space show significantly less macrophage (CD68, CD11b), myofibroblast (SMA) and general cellular deposition (DAPI) on Z2-Y12 
spheres. Scale bars, 200 μm; n = 3. Brightfield images of the stained spheres are inset; scale bars, 100 μm. c Western-blot analysis of protein extracted from the 
top three alginate analog spheres and control spheres in a; n = 3. Blots were stained for SMA and loading was normalized to β-actin. Dots represent measurements 
from individual biological replicates, and lines show the average of the three replicates. One-way ANOVA with Bonferroni correction was used to allow for statistical 
comparison of multiple means. #P < 0.05; **P < 0.001; ns, not significant. d Collagen content using a hydroxyproline quantification assay of protein extracted from 
the top three alginate analog spheres and control spheres in a. n = 3. Dots represent measurements from individual biological replicates and lines show the average of 
the three replicates. One-way ANOVA with Bonferroni correction was used to allow for statistical comparison of multiple means. #P < 0.05; **P < 0.001; ns, not 
significant. Reprinted from ref. [28], with permission from Springer Nature. 
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fibrotic processes around the capsules [30]. Studies in mice, dogs, and 
pigs showed a significant reduction in these processes. Finally, rat 
pancreatic islets immobilized in SB-SLG20 microbeads (control group 
with SLG20), were transplanted, for 200 days, into the peritoneal cavity 
of streptozotocin (STZ)-induced C57BL/6J diabetic mice and four out of 
six mice maintained normoglycemia by the end of the study (the shortest 
duration of glycemic control was ~135 days) (Fig. 3). An intraperitoneal 
glucose tolerance test (IPGTT) 200 days after transplantation, showed 
that the mice (cured ones, n=3) in the SB-SLG20 group cleared blood 
glucose (BG) and restored normoglycemia at a rate comparable to that of 
non-diabetic mice. An ex vivo glucose-stimulated insulin secretion (GSIS) 
of islets retrieved from cured mice (n=3) indicated again the normal 
function of islets. Dark-field microscopic images and hematoxylin-eosin 
(H&E) histological analysis of retrieved SB-SLG20 microcapsules from 
normoglycemic mice after 200 days revealed no or minimal cellular 
deposition on the microcapsules and the presence of numerous func-
tional islets inside. 
Microencapsulation systems based on the gelation of alginate mainly 
use barium and calcium as crosslinking agents and, in some cases, 
strontium [31]. Today there is no clear preference between calcium or 
barium and its use depends mainly on the protocol adopted in the 
different research groups. The arguments in favor of using calcium as a 
crosslinking ion revolve around the lower toxicity [32]. However, the 
resistance of the spheres cross-linked with calcium is lower than that 
achieved with barium, and that is why other groups opt for this option 
when developing their systems [28,29]. Some authors argue that, 
barium-cross-linked beads could be significantly less immunogenic as 
they do not need subsequent coatings to increase the immunoisolation, 
which are usually necessary when calcium is selected as the crosslinker 
[33]. This last statement is still in doubt, since some studies seem to 
indicate that the level of immunoisolation would not be sufficient in the 
barium beads if they do not have posterior coatings. In addition, the in 
vivo implantation of alginate and barium beads have originated a 
fibrotic response to the implant in different administration routes [26]. 
On the other hand, the release of cross-linking ions must also be taken 
into account, especially when barium is selected, due to its toxicity [34]. 
However, despite the advantages of alginate, there are still aspects 
that need to be optimized. Among them its mechanical properties, since 
the systems made with alginate and different ions tend to undergo 
changes in size due to the osmotic processes that occur in the physio-
logical environment, increasing the permeability of the capsule, weak-
ening its structure and finally causing rupture of the system [31]. 
Ion concentration, the selected crosslinking agent or the alginate 
composition are determining factors in obtaining adequate and homo-
geneous gelation. Simply varying the gelling conditions, the spatial 
distribution of the alginate chains in the microsphere can vary from 
homogeneous to very heterogeneous, with up to 10 times more con-
centration on the surface than in the nucleus [31]. Some studies have 
suggested that a truly homogeneous distribution of alginate chains can 
only be achieved by internal and external gelation applied simulta-
neously [35]. 
Release of components from the microcapsules can also stimulate an 
inflammatory response. This includes degradation products that may 
arise from reactions occurring under physiological conditions, de-
tachments of parts of the system or ion exchange, among others. Algi-
nate is subjected to hydrolytic and enzymatic degradation. It has been 
described to have a very low rate of hydrolysis at physiological pH and 
the low molecular weight chains released are excreted via the urinary 
tract. These degradation processes have been extensively studied, in vitro 
and in vivo [36,37], in the subcutaneous space, the peritoneum and in 
Fig. 3. Sulfobetaine-alginate (SB-SLG20) microcapsules improve diabetes correction in mice in a 200-day study. a Blood glucose concentrations of mice (n=6 
mice per treatment group). b Intraperitoneal glucose tolerance test (IPGTT) before retrieval (n=3). c Ex vivo glucose-stimulated insulin secretion test (GSIS) of the 
retrieved rat islets from SB-SLG20 microcapsules, n=3, Mean±SEM, *P<0.05. d A dark-field phase contrast image of retrieved islet-containing SB-SLG20 micro-
capsules. (n=6; scale bar, 2mm). e An hematoxylin-eosin (H&E) stained cross-sectional image of retrieved islet-containing SB-SLG20 microcapsules. Scale bar, 
500μm. f Immunohistochemical staining of rat islets in retrieved SB-SLG20 microcapsules. Insulin is stained red and nuclei are stained blue (Scale bar: 50μm). g A 
dark-field phase contrast image of retrieved islet-containing SLG20 microcapsules. (n=6; scale bar, 2mm). h An H&E stained cross-sectional image of retrieved islet- 
containing SLG20 microcapsules. Scale bar, 500μm. i Immunohistochemical staining of rat islets in retrieved SLG20 microcapsules. Insulin staining is negative and 
nuclei are stained blue. Scale bar, 500μm. Reprinted from ref. [30] http://creativecommons.org/licenses/by/4.0/. 
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some areas of the brain. 
Some groups have devised strategies to improve the mechanical 
stability of alginate hydrogels, covalently crosslinking it with different 
polymers, via photocrosslinking solutions or enzymatic reactions, for 
example [38–40]. In a recent study, sodium alginate was functionalized, 
with cross-reactive PEG derivatives presenting a terminal thiol and 
carbon electrophile functionalities, and the spheres formed by a com-
bination of Ca-alginate interactions and sulfur-carbon covalent bonds. 
The resulting spheres showed greater mechanical resistance and better 
preserved shape, compared to the simple alginate and calcium beads. 
When these spheres were implanted in the intraperitoneal space of 
immunocompetent mice, tissue adherence was not observed and integ-
rity was not compromised in the 30 days of the study [41]. In another 
interesting study, it was shown that modifying the alginate with 2-ami-
nomethyl methacrylate hydrochloride can decrease immune reactions 
against the implant. The authors performed a first ionic crosslinking, 
followed by the application of UV light to form the covalent bonds. This 
showed greater mechanical stability when it was evaluated in vivo for 3 
weeks [42]. 
Material selection is especially demanding in this type of system 
since the resulting particles must not only have a high durability after 
implantation, they must also be capable of responding to the biological 
needs of the immobilized cells for long periods of time. However, many 
materials, such as alginate, do not have cellular signaling motifs and 
must be biofunctionalized to improve their interaction with encapsu-
lated cells. In this regard, in recent years, different proteins — such as 
collagen, laminin or fibronectin — or small short peptides — such as 
RGD (arginine-glycine-aspartic acid) — have been incorporated into 
microcapsules, trying to imitate the physical and biomechanical char-
acteristics of the native environment of the encapsulated cells to 
improve and control cellular behavior [43–46]. In this regard, there are 
divided opinions on whether it is more appropriate to use complete 
extracellular matrix proteins, such as fibronectin or collagen, or small 
synthetic peptides, such as RGD [47,48]. Interestingly, the best strategy 
in every case seem to be strongly cell-dependent. 
For example, Garate et al. evaluated the influence of RGD function-
alization of alginate encapsulating C2C12 myoblasts, baby hamster kid-
ney (BHK) fibroblast or stromal mesenchymal cells (MSCs) and the 
results showed different optimal concentrations of RGD in every case 
[47,49,50]. In this sense, Gonzalez-Pujana et al. designed a sensitive 
analytical tool that permits the evaluation of different cell adhesion 
kinetics, but also the integrin profiling and their contribution to cell 
attachment and adhesion strengthening via clustering, which allows the 
design of specific biofunctionalization strategies depending on the cell 
type [51]. 
Other components of the extracellular matrix (ECM), such as hyal-
uronic acid (HA) have also been added to the alginate matrix of mi-
crocapsules. Recently, pancreatic pseudo-islets derived from MSCs were 
immobilized in alginate-HA microcapsules and the results showed better 
cell viability, with lower levels of initial apoptosis [52]. Moreover, the 
inclusion of HA in the alginate matrix, enhanced the differentiation of 
the MSCs towards pancreatic progenitors and increased the insulin 
release [53,54]. 
2.1.2. Coating materials 
In some cases, and depending on the application, the microbeads 
composed of different biomaterials and cells, are the final product to be 
administered. However, obtained pore size in most cases is too large and 
does not present a real barrier against the threats that the implant will 
face once implanted. Therefore, many groups coat these beads with 
different polymers to elaborate microcapsules that control the molecules 
and cells that can come into contact with the immobilized cells. 
Currently, this filtering is carried out by defining a minimum molecular 
weight — molecular weight cut-off (MWCO) — of solute that is totally 
excluded by the semipermeable membrane [55]. This definition can be 
misleading since molecules of similar molecular weight can have very 
different sizes, as is the case with proteins and polysaccharides. 
Today, there is still no consensus regarding what should be the most 
optimal criterion for the exclusion of molecules that can access the 
interior of the microcapsule, despite Chick et al. already named the 
concept of the immuno-barrier in 1977 [56]. Adequately defining this 
concept is essential to develop biocompatible and biotolerable systems 
and it should be a priority issue. 
To create a biocompatible and biotolerable environment, the semi-
permeable membrane must first avoid contact of the encapsulated cells 
with the cellular components of the immune system and the antibodies. 
A MWCO of around 70 kDa seem to be adequate for many drug delivery 
applications, but it has been found that this is not enough if bi- 
directional flow of antigenic, chemotactic and cytotoxic molecules — 
such as reactive oxygen species or pro-inflammatory cytokines — is 
allowed. With the classic approach of size-exclusion, low molecular 
weight molecules such as IL-1β (17.5 kDa) or TNF-α (51 kDa) will be able 
to easily access the interior of the capsule and cause damage to the 
encapsulated cells, as they are even smaller than some of the therapeutic 
molecules that are usually released from these systems. On the other 
hand, encapsulated cells secrete antigens — e.g. chemokines as low as 8- 
13 kDa in molecular weight — to the exterior of the microcapsules that 
are responsible for recruiting cells from the host immune system. 
For the elaboration of the semi-permeable membrane, different 
polymers have been used, such as chitosan, oligo-chitosan or poly 
(methylene-co-guanidine) (PMCG), but both in preclinical studies and 
in human trials, the most used molecules are poly-L-lysine (PLL) and 
poly-L-ornithine (PLO) [57–59]. However, both molecules are known to 
be immunogenic, so many groups choose to add a last layer of alginate 
on the particles to mask the positive charges that would otherwise be 
exposed to the components of the immune system. Resulting micro-
capsules are known as APA (alginate-poly-L-lysine-alginate or alginate- 
poly-L-ornithine-alginate) [60,61]. This strategy has been intensely 
debated since there are studies showing that this second layer of alginate 
may not be sufficient to inactivate all the exposed positive charges 
[62–64]. In fact, the studies carried out to analyze the surface of the 
microcapsules coated with these polycations, showed that these mole-
cules are exposed — and in great quantity — in the outermost 1-2 
monolayers of the membrane, thus the outer alginate layer appears to 
overlap with the PLL layer, rather than form an additional outer mem-
brane [65,66]. In addition, both polycations show limited physico-
chemical properties but most works chose PLO for apparently having 
greater mechanical stability, biocompatibility and permeability [63]. 
The increased immunogenicity of microcapsules coated with this 
type of polycations is mainly due to the physicochemical changes that 
affect protein adhesion on the surface of the microcapsules, such as zeta 
potential, hydrophobicity or roughness. On the one hand, the zeta po-
tential of this type of implant must be negative and similar to that of the 
membranes of adjacent cells. In a study carried out by De Vos et al. [67], 
it was found that the zeta potential of APA-PLL microcapsules showed a 
more negative value before they were implanted. Although all the values 
were less negative than those described in other studies for the uncoated 
alginate microbeads [68]. On the other hand, in a study carried out by 
Lekka et al. [69], a lower surface roughness, of less than 1 nm deep, was 
associated with the uncoated alginate microspheres and with the PLL- 
coated microcapsules, compared to much higher values, of up to 14.4 
nm, of PMCG-sulfate coated microcapsules. Finally, the addition of 
coatings to the alginate microbeads increases the hydrophobicity of the 
system [63], although the type of alginate used in each case also in-
fluences the final result. 
In a very interesting study by Rokstad et al. [62] a lepirudine-based 
human whole blood model was used as a tool for measuring the 
biocompatibility of different microcapsules. The results showed that 
alginate polycation (AP) or APA capsules trigger the complement acti-
vation, whereas Ca/Ba alginate do not. Fig. 4 shows that the deposition 
of complement component 3 (C3) on the bead surface is higher in AP or 
APA beads than Ca/Ba beads. 
T.B. Lopez-Mendez et al.                                                                                                                                                                                                                      
Journal of Controlled Release 335 (2021) 619–636
625
Taking into account the obvious need to improve the coatings of 
these particles, in recent years several groups have analyzed other 
molecules that may be appropriate, both to substitute the PLL/PLO 
molecules or in combination with them [70–72]. In a recent study, 
genipin was used in association with PLL [73]. Using force spectroscopy- 
based simultaneous topographical and mechanical characterization to 
study polymer to polymer interaction, the study concluded that genipin 
crosslinking avoided membrane detachment in alginate microspheres 
with double polycation coatings. 
Attempts have also been made to improve the biocompatibility of the 
microcapsules by coating them with polymers capable of reducing 
protein adsorption and the fibrotic response to the implant. By coating 
the alginate microcapsules with hydrophilic polymers such as PEG 
[74–76], the biocompatibility of the implant can be improved, although 
the level of protein adsorption will depend on the density, length and 
conformation of its chains. In one study, alginate-PEG microcapsules 
containing allogenic islets were evaluated and their biocompatibility 
was improved when transplanted into the intraperitoneal space, but not 
into the epididymal fat pad [77]. The strategy of coating the alginate 
microcapsules with PEG and rapamycin, evaluated by another group, 
was also able to reduce macrophage proliferation and fibrotic response 
[78]. 
Modifying the surface of the microcapsules with a patented macro-
molecular heparin conjugate has also been shown to improve biocom-
patibility and significantly reduce the fibrotic response against the 
implant, in syngeneic and allogeneic transplant models [79]. With a 
similar strategy, but coating the alginate microcapsules with the C-X-C 
motif chemokine 12 (CXCL12) (also known as "stroma-derived factor 1", 
SDF-1), the biocompatibility was also improved but, in this case, a long- 
term improvement in xenogeneic pancreatic islet survival and 
Fig. 4. Deposition of C3 on the microsphere surface after incubation in human lepirudin anti-coagulated whole blood. A–L 3D projections made by 
sectioning entire microspheres after incubation for 30, 120 and 360 min. M–P Projections through the equator overlaid with transmitted light images after 360 min. 
Q–T Controls are given in the lower panels as projections (black pictures). The inserts show transmitted light equatorial sections for visualization. Bars are 100 μm. 
Reprinted from ref. [62] with permission from Elsevier. 
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functionality was also achieved, due to the recruitment of immuno-
suppressive regulatory T cells to the implant site [80]. Recently, in 
another study, coating the alginate spheres with chitosan also signifi-
cantly reduced the fibrotic response against the implant, improving its 
biocompatibility, while maintaining glucose levels for one year, in a 
canine allogeneic transplant model and in a xenotransplant in rodents 
[81]. 
Another strategy that may be very interesting is to incorporate motifs 
that have anti-inflammatory properties into the design of the micro-
capsule. Sulfated alginates [82] or the interleukin-1 receptor (IL-1R) 
[83] are good examples of this, as they decrease the production of some 
cytokines and improve the viability of encapsulated cells. 
In some systems, such as those made by the alginate-PLL combina-
tion, it is not possible to independently adjust the mechanical stability 
and the permeability of the microcapsules, which is a notable limitation 
[84]. However, there are studies in which this permeability-stiffness 
relationship has been divided using various polymers [85]. The possi-
bility of independently modifying critical parameters for cell encapsu-
lation, such as capsule size, thickness, mechanical resistance and 
membrane permeability, offers great advantages in the design of this 
type of system. 
Poor mechanical resistance can lead to protrusion of encapsulated 
cells, a phenomenon that needs to be fixed when designing these systems 
[86]. In this sense, Johnson et al. carried out an analysis quantifying cell 
protrusion in alginate microcapsules, coated with PLL and 50% hydro-
lyzed poly(methylvinylether-alt-maleic anhydride) (PMM). According 
to the results obtained, around 30% of the encapsulated INS-1E β cells 
were located in the last 20 μm of the alginate-PLL-PMM50 layer, with 
7% of the cells protruding [87]. Reinforcing the capsules with cross- 
linked shells may help preventing cell exposure and scape. 
Lastly, in some cases, for example if the secreted molecule is espe-
cially large, it will be necessary to optimize the system so that it allows 
the passage of the therapeutic molecule out of the capsule, without 
compromising the protection of the encapsulated cells. In this sense, 
recently Montanucci et al. modified the permeability of alginate mi-
crocapsules to allow the continuous secretion of immunoglobulin M 
(IgM), with no signs of inflammation [88]. 
2.2. Cell source and target pathology 
Both allogenic and xenogeneic cells have been incorporated into the 
microencapsulation systems. In case of human origin cells, their acqui-
sition can be complicated and expensive. Besides, they can be subject to 
biological, ethical and legal limitations. Therefore, the use of xenogeneic 
cells has spread in the field of cell microencapsulation, thanks to the 
immunoisolation produced by the semipermeable membrane [89]. 
However, the systems used to date to encapsulate both cell types have 
been practically identical, without taking into account that the different 
immunological responses caused by allogenic or xenogenic cells require 
capsular configurations capable of protecting the cellular content 
against variable immunological environments. 
In the case of allogeneic transplants, it is probably sufficient to avoid 
contact between the encapsulated cells and the cells of the host's im-
mune system [90]. Therefore, the simplest microcapsules of cations and 
alginate, without great limitations in the diffusion of molecules, may be 
suitable. When a xenotransplantation is performed, the scenario is more 
complex and the simplest systems may not be effective in avoiding im-
mune rejection (Fig. 5). These cells produce xenogenic epitopes, such as 
galactosyl (Gal) residues, that are secreted outside the capsule and are 
recognized by the immune system of higher mammals, including 
humans. In addition, in recent years the role of N-glycolyl neuraminic 
acid (Neu5Gc), another pig xenoantigen, is being studied as a possible 
obstacle in xenotransplantation [91]. 
The complexes formed by Gal residues and the antibodies linked to 
them, are powerful activators of the classical complement pathway. As 
these complexes begin to accumulate on the capsular surface, chemo-
taxis of different cell types, such as neutrophils [92] occurs, which 
initiate powerful inflammatory reactions. During this first phase, many 
Fig. 5. Pro-inflamatory molecule secretion from the microcapsules activates the immune response in different scenarios. Xenogeneic transplant. Some 
antibodies are able to enter the capsule or contact the encapsulated cells located in the most superficial layers of the implant. These antibodies recognize sequences 
that are not present in the host species, such as the Gal carbohydrate in the case of primates, and this leads to the activation of complement pathways. This activation 
produces direct cell lysis and the release of molecules that promote inflammation and the recruitment of immune cells, such as neutrophils, to the implant site. The 
recruited cells release small cytokines that can cross the microcapsule membrane and damage the encapsulated cells. In more advanced phases, fibrotic processes 
appear, which could end up isolating the implant and compromising the supply of nutrients and oxygen to the interior of the capsule. Intracapsular necrosis. 
Necrotic cells release the so-called DAMPs or alarmins, such as high-mobility group box-1 (HMGB1), heat shock proteins (HSPs), S100 proteins, DNA/RNA fragments 
etc., to the extracellular fluid. These small molecules can diffuse outside the microcapsules and activate cells of the immune system, such as macrophages, dendritic 
cells, neutrophils or lymphocytes, binding PRRs, such as TLRs. These cells, in response, will secrete pro-inflammatory cytokines, such as IL-1β, IL-6, interleukin-8 (IL- 
8), or TNF-α, which will produce inflammation and recruit more immune cells to the area. These molecules can enter the microcapsules and damage the encapsulated 
cells. If the situation persists over time, the adaptive immune response may be activated. 
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small cytokines are able to cross the semipermeable membrane of the 
microcapsules, causing damage to the encapsulated cells. 
Following the first innate response, a second IgM-mediated [92] 
delayed hypersensitivity response to xenogeneic epitopes begins, pro-
moting the recruitment of new cells of the immune system to the implant 
site and the secretion of more chemokines and cytokines. After these 
events, the microcapsules are usually surrounded by inflammatory cells 
and fibroblasts that hinder the passage of nutrients and oxygen, 
compromising the survival of the encapsulated cells. Finally, the 
appearance of fibrosis can lead to total isolation of the implant. 
Due to these differences between allo and xenografts, the latter 
require systems that protect encapsulated cells against more potent 
threats. The membranes must be less permeable and, ideally, prevent the 
passage of molecules produced by the immune system, while preventing 
the exit of hyperinflammatory xenogeneic epitopes, such as Gal residues. 
Another way of activating the immune response may occur when cell 
necrosis appears inside the microcapsules [93] (Fig. 5). Unfortunately, 
this is still quite common, when there are problems in the diffusion of 
nutrients and oxygen, due to insufficient permeability of the bio-
materials, fibrotic processes associated with foreign body reaction or an 
excess of encapsulated cell mass [94]. Necrotic phenomena are directly 
related to damage-associated molecular patterns (DAMPs). These mol-
ecules are normally found inside the cells, but are released outside when 
cell damage occurs [95]. Some examples are heat shock proteins or 
DNA/RNA fragments. The mammalian immune system has specific re-
ceptors for this type of signals, the PRRs, such as Toll-like receptors 
(TLRs). The DAMPs released from the microcapsules are powerful acti-
vators of the immune system, activating inflammatory and angiogenesis 
processes, which mediate the release of large amounts of cytokines that 
jeopardize the survival of the encapsulated cells [96]. 
In this sense, there are different studies that tried to improve the 
viability of microencapsulated cells, incorporating chemical compounds 
capable of generating oxygen [97,98] or through strategies that promote 
the vascularization of the implant. For the latter, several strategies have 
been tested. On the one hand, the ability of different angiogenesis- 
inducing growth factors, such as fibroblast growth factor (FGF) 
[99,100] or vascular endothelial growth factor (VEGF) [101,102] has 
been exploited to promote the neovascularization of the implant, thus 
improving the results of the therapy. On the other hand, the implanta-
tion of the microcapsules in pre-vascularized spaces is also considered as 
a beneficial option, either generated in the host’s organism or in mac-
rodevices [103,104]. 
Even if the risks associated with xenotransplantation are being 
reduced, the advances in the field of stem cell use have unlocked an 
unthinkable potential. The ability to differentiate human stem cells, 
from different sources, to obtain the desired cell type or the possibility of 
reprogramming adult cells to induced pluripotent stem cells (iPSCs) 
[105,106] have defined the path to a sufficient source of human cells. 
Furthermore, in the particular case of iPSCs, there are not ethical re-
strictions [107]. 
In this vein, the studies carried out to date have shown that it is 
possible to obtain fully functional beta cells or pancreatic progenitors, 
starting from human pluripotent stem cells (hPSCs) — either human 
embryonic stem cells (hESCs) [108–113] or iPSC [114]. In recent years, 
these cells, known as human stem cell derived β cells (SC-β), have been 
seen as an excellent source of unlimited pancreatic cells [30,111,115]. 
For example, Vegas et al. implanted human SC-β, immobilized on algi-
nate beads, in the intraperitoneal space of immunocompetent C57BL/6J 
mice previously treated with streptozocin. C-peptide levels and blood 
glucose concentration showed therapeutically relevant results up to 174 
days, without the need for immunosuppressive treatment [116]. In 
another recent study, the maturation of SC-β was stimulated by forming 
aggregates, similar in size to pancreatic islets, which make them respond 
to glucose stimulation in just 3 days after transplantation [117]. 
Likewise, stem cells from other origins, such as amniotic fluid or 
adipose tissue, can also be transformed into insulin-producing cells, 
which can be encapsulated and transplanted in diabetic animal models 
to normalize blood glucose values [118–120]. For example, Montanucci 
et al. managed to remit hyperglycemia in diabetic mice, implanting 
human umbilical cord Wharton jelly-derived mesenchymal stem cells 
(hUCMS), immobilized in alginate and PLO microcapsules [121]. 
Moreover, in a more recent study by the same authors [122], hUCMS 
cells were co-encapsulated with human pancreatic islet-derived pro-
genitor cells (hIDC) and implanted into non-obese diabetic mice. The 
objective of this synergy was to maintain tracer insulin output by hIDC, 
while exploiting the immunoregulatory properties of hUCMS. A decline 
of blood glucose levels was observed in vivo. 
MSCs have demonstrated to be very suitable for their use in cell 
encapsulation systems, due to their hypoimmunogenic and immuno-
modulatory characteristics [123–125]. These cells inhibit immune re-
sponses by secreting cytokines and soluble growth factors that produce a 
local immunosuppressive effect in the surrounding cells [126]. In recent 
studies, efforts have focused on analyzing the behavior of immortalized 
MSCs, genetically modified to secrete erythropoietin (EPO), for the 
treatment of anemia [50,127–129]. In addition, their benefits have also 
been evaluated in hepatic pathologies [130,131], as an alternative to 
porcine hepatocytes [132,133]. Moreover, MSCs not only are a very 
interesting option as a secretory cell [50,128], but also as a co- 
encapsulated auxiliary cell [134–137]. In a recent study, pancreatic is-
lets and MSCs were co-encapsulated in alginate and PEG microcapsules 
and implanted into the intraperitoneal space of a diabetic mouse model 
[138]. The results showed that MSCs interact with N-cadherin and in-
crease insulin secretion, in addition to providing structural support to 
the islets, improving their viability and functionality. 
It is also important to highlight that the customizable environment 
generated in these 3D structures can notably improve cell viability and 
cellular function. In this regard, cell microencapsulation technologies 
are used far beyond sustained release purposes, for example, for 
enhanced cell culture [139] or for recapitulating tumor microenviron-
ment or in vitro disease models [140], among others. 
2.3. Microcapsule size and shape 
The optimal size for cell microencapsulation systems remains a 
matter of debate. On the one hand, it is evident that a larger capsule size 
could be an obstacle for the diffusion of nutrients and oxygen to the 
nucleus of the system. This would lead the encapsulated cells to situa-
tions of hypoxia and cell death, as well as to slower responses to the 
stimuli from their environment [141]. In fact, in a recent study, it was 
suggested that, in the case of pancreatic islets, the maximum distance 
between these and the extracapsular fluid should not be more than 100 
μm, to allow adequate exchange of nutrients and oxygen [142]. 
Therefore, many have been the studies aimed at obtaining smaller 
capsules. Coaxial air flow and flow focusing technologies were presented 
as attractive alternatives to the usual methods of making microcapsules 
by means of electrostatic dripping, making it possible to manufacture 
capsules of 100-200 μm in diameter, that allow for more complicated 
routes of administration, such as intracranial administration (in the case 
of CNS pathologies) or even intravitreal [143,144]. Furthermore, trying 
to reduce the size of the capsules as much as possible, in recent years 
nanoencapsulation strategies have also been evaluated — such as 
conformal coating or layer-by-layer coating —, especially for the 
immunoprotection of the islets of Langerhans [124]. 
Conformal coating is a form of non-spherical encapsulation that re-
duces the diffusion distance and the volume of the implant [145]. 
However, the process often involves multiple steps that can cause 
damage to the encapsulated cells, and a conclusion has not yet been 
reached regarding whether these type of coatings are thick enough for 
their use in clinical practice [146,147]. Some studies [148] have sug-
gested that the conformal coating has a lower immunoprotective ca-
pacity, compared to hydrogel microcapsules, but in recent years several 
new strategies have demonstrated the potential of this technology 
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[149–151]. 
In case of layer-by-layer coatings, layers of polymers of opposite 
charges alternate on the surface of a group of cells, decreasing the 
biomaterial/cell ratio and thus improving the diffusion of the thera-
peutic molecule. In theory, this strategy should improve some of the 
most characteristic limitations of conformal coatings, such as inade-
quate mechanical stability or limited immunoprotection. Layer-by-layer 
coatings have been evaluated in several studies in rodents, with prom-
ising results [152–154] and in a recent study in non-human primates, 
layer-by-layer encapsulated pancreatic islets with 3 layers of PEG had 
100% survival during 150 days after xenotransplantation — in the 
presence of immunosuppressive treatment —[155,156]. 
However, the polymers used to nanoencapsulate therapeutic cells are 
usually less biocompatible than other hydrogels normally used in the 
field of cell microencapsulation. Furthermore, the shape and roughness 
of the implant surface produce notable differences in the immune 
response that it causes. Therefore, in nanoencapsulation, it might be 
interesting to add a second type of coating that attenuates the shapes 
and complements the system [157]. 
On the other hand, and in opposition to the idea of reducing size as 
much as possible, Veiseh et al. published a complete study analyzing the 
influence of the size of the alginate microspheres (containing or not 
Langerhans islets) in rodents and non-human primates. Their conclu-
sions, validated also with other materials such as ceramics, metals and 
plastics, indicated that the larger microspheres (1.5 mm) had a smaller 
number of immune system cells and fibrotic processes in all cases [158] 
(Fig. 6). When implanted for 14 days into the intraperitoneal space of 
C57BL/6 mice, the Ba+2-crosslinked SLG20 alginate hydrogel spheres, in 
eight different sizes (0.3-1.9 mm), showed a marked reduction in 
cellular deposition and fibrosis onto spheres as their size increased. 
Cellular deposition on spheres was examined using Z-stacked confocal 
imaging using DAPI (nucleus marker), F-actin (cellular cytoskeleton 
marker) and α-SMA (myofibroblast marker). Additional immunostain-
ing for the host immune cell markers CD68 (macrophage), Ly6G/Ly6C- 
GR1 (neutrophil) and TGF-β (inflammation marker) also showed 
reduced immune cell deposition on larger spheres, and this result was 
confirmed by qPCR expression analysis of additional fibrosis markers - 
namely collagen 1a1 (Col1a1), collagen 1a2 (Col1a2) and α-SMA - and 
by western blot analysis of α-SMA expression within the cellular over-
growth on spheres. 
This study has led to an opinion division among the experts in the 
field [27]. In fact, some of them have criticized that the study did not 
take into account the degree of purity of the alginate used, one of the 
factors considered key to predict the expected inflammatory response 
[159]. 
Finally, it is important to highlight that there are many factors 
influencing bead formation and that many of them are not properly 
described yet. In a recent study, the impact of several parameters (such 
as, critical electric potential, needle size or distance between the needle 
and the gelation bath) on electrostatic-droplet formation was investi-
gated and their influence was described through equations to make 
procedures more reproducible and allow optimal control of capsule size 
and properties [160]. 
2.4. Implant site and administration procedure 
The choice of a suitable implant site can greatly determine its 
biocompatibility and viability. Ideally, this space should be large enough 
to accommodate the required number of microcapsules and easily 
accessible for implant removal. Likewise, the neovacularization of the 
implant must be favored, while the immune response must be limited to 
avoid an excessive fibrotic response that may condition the supply of 
nutrients and oxygen to the microencapsulated cells. In this sense, when 
a systemic effect is pursued, the intraperitoneal and subcutaneous cav-
ities appear as simple and minimally invasive routes [37,161]. In fact, 
most of the studies with pancreatic islets have focused on the 
intraperitoneal route, despite the high activity of macrophages and the 
need for larger numbers of cells compared to other areas [162]. How-
ever, the neovascularization capacity in these two pathways is not suf-
ficient in some cases, resulting in inadequate therapeutic molecule 
release pharmacokinetics and a shortage of nutrients and oxygen for 
encapsulated cells, especially when pancreatic islets are used [26,157]. 
In this case, the hepatic and renal subcapsular cavities are considered to 
have some advantages over the intraperitoneal or the subcutaneous 
spaces [162,163]. 
In recent years, preserving the benefits of the intraperitoneal route 
but improving the disadvantages, in some studies the surgery to create 
an omental pouch has been proposed. This surgery can ensure a space 
large enough to accommodate the necessary number of microcapsules, 
with greater vascularization and improving one of the main problems of 
biped hosts: the aggregation of the spheres in the lower part of the 
peritoneum, which increases the shortage of nutrients and oxygen to the 
implant. This strategy has demonstrated its long-term benefits, keeping 
diabetic rodents in normoglycemia [164]. More recently, Bochenek et al. 
described the implantation of allogeneic pancreatic cells encapsulated in 
Z1-Y15 alginate beads in a similar omental pouch in non-human pri-
mates [29] (Fig. 7). To perform the bursa omentalis transplantation 
technique, a small incision was introduced laparoscopically into an 
avascular section of the gastrocolic ligament. The spheres were then 
infused into the bursa omentalis. Over time, the spheres distributed 
uniformly as a monolayer between the two vascularized omental layers. 
This administration site was compared to other anatomical sites. The 
bursa omentalis showed a trend of increased average pO2 compared to 
the general intraperitoneal space, but this was not found to be signifi-
cantly different (35.1±3.2 mmHg compared with 30.7±1.6 mmHg, 
respectively). The kidney capsule was found to yield the highest pO2 
measurements compared to other sites (48.7±1.3 mmHg). 
Regarding the renal subcapsular space, although the vascularization 
in this area is greater than in other areas, the space is more limited and it 
is difficult to administer the necessary large implant volumes. As a mere 
example, in a study carried out in 7 macaca fascicularis xenotransplanted 
in the renal subcapsular space with microencapsulated pancreatic islets, 
porcine C-peptide was detectable in 2 of the animals for 60 days after 
administration [165]. 
Finally, regarding the subcutaneous route, some authors argue that it 
may still be attractive due to some remarkable advantages such as being 
less invasive, allowing the easy monitoring and retrieval of the implant 
and showing a lower immunogenic activity [26]. 
On the other hand, when a local release of the therapeutic molecule 
is sought, the administration must be carried out near the target tissue. 
Clear examples of this are the eye [166] or CNS [167], in which the 
natural barriers prevent the systemic administration. These two routes 
are considered to be immune-privileged and thus lower immunological 
responses are expected after implantation. Another situation that re-
quires local administration is when the objective of the micro-
encapsulated cells is the conversion of a prodrug into an active molecule, 
exclusively near a tumor, to avoid the adverse events derived from a 
systemic exposure [168]. 
In any case, the viability of the implant will largely depend on the 
lack of any fibrotic capsule that could isolate the encapsulated cells. In 
order to reduce the fibrotic response, some groups have described the 
benefits of concomitant administration of immunosuppressive mole-
cules locally or temporarily, just a few days after implantation. The 
incorporation of drugs, such as ketoprofen or dexamethasone within the 
microcapsules has been tested in several studies, in which the fibrotic 
response has been reduced [169–171]. More recently, the CXCL12 
molecule was co-encapsulated together with SC-β derived from hPSCs, 
with the aim of reducing the fibrotic pericapsular response, in the 
absence of systemic or local immunosuppressive treatments. CXCL12 
produced an increase in insulin secretion by the encapsulated cells and 
the implant remained viable for more than 150 days in immunocom-
petent mice [172]. The same strategy was also used in non-human 
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Fig. 6. Increasing alginate sphere size results 
in reduced cellular deposition and fibrosis 
formation on the spheres. SLG20 alginate 
spheres (0.5ml in volume) of different sizes (0.3, 
0.4, 0.5, 0.6, 0.7, 1, 1.5 and 1.9 mm) were 
implanted into the intraperitoneal space of 
C57BL/6 mice, where they were retained for 14 
days and analyzed for degree of fibrosis upon 
retrieval. a Dark phase contrast images obtained 
from retrieved spheres reveal a significant 
decrease in level of cellular overgrowth with 
increase in sphere size; scale bar = 2mm. b Z- 
stacked confocal images of retrieved spheres 
immunofluorescence stained with DAPI (high-
lighting cellular nuclei), phalloidin (highlighting 
F-actin) and α-Smooth Muscle Actin (α-SMA, 
myofibroblast cells); Scale bar = 300 μm. c q- 
PCR based expression analysis of fibrotic 
markers α-SMA, d collagen 1a1 and e collagen 
1a2 directly on the 8 various sized (0.3, 0.4, 0.5, 
0.7, 0.9, 1, 1.5, 1.9 mm) spheres plotted 
normalized to relative expression levels on 300 
μm sized spheres. f Semi-quantitative western- 
blot analysis of α-SMA expression in cell over-
growth from on microspheres (1-5 labeling of 
bands corresponds to individual mice). g Plot of 
analyzed band intensities from western blot im-
ages shown in f. Error bars, mean ± SEM. N = 5 
mice per treatment. All experiments were per-
formed at least three times. qPCR and western 
blot statistical analysis; one-way ANOVA with 
Bonferroni multiple comparison correction *:p <
0.05, **: p <0.001, and ***: p < 0.0001. 
Reprinted from ref. [158] with permission from 
Springer Nature.   
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primates (n = 4) but the results are still preliminary [173]. Toll-like 
receptor 2- modulating pectin – polymers, with varying degrees of 
methyl-esterification (DM) have also been used in alginate-based mi-
crocapsules, in order to attenuate immune responses and support islet- 
xenograft survival [174]. DM18-pectin/alginate microcapsules showed 
a significant decrease of DAMP-induced Toll-Like Receptor-2 mediated 
immune activation in vitro and, when implanted in vivo, pericapsular 
fibrosis was reduced. In another study [175], a crystalline Colony 
Stimulating Factor 1 Receptor (GW2580) inhibitor was encapsulated 
with human islets in alginate microbeads, and transplanted into the IP 
space or injected subcutaneously in STZ-induced diabetic C57BL/6 
mice. Drug-loaded beads in both IP and SC sites were equally capable of 
restoring glycemic control in diabetic mice for extended periods of time 
up to 72 days. In contrast, SC capsules without drug did not provide 
control of blood sugar. 
3. Biosafety: dose control, monitorization and extraction 
Once the implant has been placed, real-time monitoring of its loca-
tion and correct operation can give us valuable information. The exact 
location of the microcapsules can be determined by cellular labeling 
with fluorescent dyes or radiolabels [176,177], traditional imaging 
systems, such as ultrasounds [178] or, more commonly, by high reso-
lution and contrast magnetic resonance imaging (MRI) [179–183]. 
There are different types of contrast materials that can be used with 
these techniques. One of the most studied examples are the super-
paramagnetic iron oxide nanoparticles (SPIO) [184]. 
It is also possible to detect microcapsules by X-ray, if we encapsulate 
contrast agents such as barium sulfate or bismuth sulfide, which make 
them opaque [185]. In one study, a method based on gold nanoparticles 
was developed as a contrast agent to monitor alginate microcapsules by 
X-ray and micro-CT [186] techniques. The same group demonstrated 
that it is possible to detect alginate microcapsules both in vitro and in 
vivo, through low exposure to X-rays, if they are coated with gold 
nanoparticles [187]. On the other hand, different groups have found 
other innovative ways to monitor implanted microcapsules. For 
example, researchers have recently developed a type of microcapsule 
with intrinsic capacity for in vivo imaging by incorporating genipin into 
its own design [188]. Different volumes (50-200 μL) of capsules were 
implanted into the subcutaneous space of NSG mice. Taking advantage 
of the natural fluorescence of this compound, they demonstrated the 
linear correlation between the implanted microcapsule volume and the 
signal emitted by the microcapsules for 35 days. Thus, through this 
strategy, it is possible to assess the actual injected dose — volume of 
microcapsules — after administration and monitor the position of the 
implant over time, which improves in a remarkable manner the 
biosafety and efficacy of the therapy (Fig. 8). 
Molecular imaging techniques not only allow us to monitor the exact 
location of the implant, but also to simultaneously confirm the viability 
and functionality of the encapsulated cells by including reporter genes 
that emit fluorescent and/or bioluminescent signals [189–191]. These 
techniques provide us with quantitative and real-time information, in a 
non-invasive way. Recently, Spanoudaki et al. combined fluorine MRI 
and unsupervised machine learning to monitor over time the spatial 
arrangement and the oxygen content of implants encapsulating 
pancreatic islets in vivo [192]. 
Regarding biosafety, another critical point may occur at the end of 
the therapy, or in an event where significant adverse effects are 
Fig. 7. Transplantation method (general IP space VS. 
bursa omentalis) causes differential spatial distribution of 
the Z1-Y15 alginate spheres post-implantation. a General 
intraperitoneal space transplantation: Z1-Y15 spheres were 
laparoscopically distributed around the left and right medial 
lobes of the liver within the intraperitoneal space (pink) (I). At 
1-month post-implantation, the non-fibrosed spheres had 
settled and clumped within the Douglas space (II). Bursa 
omentalis transplantation: the stomach was lifted with a 
laparoscopic grasper and a small incision was made into an 
avascular section of the gastrocoli ligament. The Z1-Y15 
spheres were then infused into the bursa omentalis (blue) 
(III). At 1-month post-implantation, the Z1-Y15 spheres 
remained spatially dispersed within the bilayer of the greater 
omentum (IV). A schematic of the two transplantation 
methods provides the location of the anatomical sites and a 
summary of the spatial distribution of the Z1-Y15 spheres 
during the 1-month retrievals (center). The general IP space 
transplantation was repeated independently for n = 10 NHP 
and the bursa omentalis transplantation for n = 7 with 
resultant similar spatial distributions. b The greater omentum 
was extracted through the supra umbilical midline incision at 
1 month and shows translucent, unattached Z1-Y15 spheres 
with encapsulated allogeneic islets within the omental tissue 
bilayer. c Partial oxygen pressures (pO2) of various trans-
plantation sites that have been previously investigated for 
encapsulated islet transplantation. The kidney capsule has the 
highest pO2 measurements compared to the other anatomical 
sites. The intramuscular space (rectus abdominis) and general 
IP space have lower pO2 compared to the pancreas, liver, 
subcutaneous and kidney capsule. The bursa omentalis site 
was not found to be statistically significantly different than the 
pancreas or the general IP space. (* p < 0.05; one-way analysis 
of variance (ANOVA) with Fisheŕs LSD for multiple compari-
sons; 3 steady-state measurements were taken for each 
anatomical site from the same primate; n = 3 NHP; box and 
whisker with median, upper and lower quartile ranges, out-
liers, 1.5 x IQR, individual data points overlaid). Reprinted 
from ref. [29] with permission from Springer Nature.   
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detected. In these situations, a system that allows us to ensure a total 
inactivation and/or removal of the implant can be necessary. For such 
aim, one of the main strategies is the inclusion of suicide genes into the 
genome of the encapsulated cells [193–195]. The enzyme-activated 
prodrug mechanism, thymidine kinase/ganciclovir system that targets 
actively dividing cells is the most frequently studied gene therapy 
strategy [195]. However, these strategy could present some disadvan-
tages when the encapsulated cells are in a slowly dividing state. In order 
to improve this problem, Wong et al. equipped glial cell-derived neu-
rotrophic factor (GDNF)-secreting cells with a proliferation independent 
Tet-on regulated pro-caspase 8 apoptotic gene switch for a safer ocular 
drug delivery [196,197]. 
Recently, Delcassian et al. developed functionalized iron oxide 
nanoparticle-loaded alginate microcapsules that enabled graft retrieval 
under an applied magnetic field [198]. In addition, this system facili-
tates graft localization via MRI. These capsules containing islets were 
evaluated both in vitro and in vivo, in immunocompetent diabetic mice, 
and they were able to restore normoglycemia for at least 6 weeks. The 
application of a magnetic field for 90 s, 24h after implantation, allowed 
the retrieval of up to 94% of the transplant volume. 
On the other hand, there is the possibility of introducing the mi-
crocapsules in a physical support that prevents their dispersion. These 
retention elements can be, for example, cements based on calcium 
phosphate or hydrogels of different composition. Acarregui et al. 
managed to improve the administration, retention and extraction of the 
APA microcapsules, administering them in injectable or preformed 
alginate hydrogels. Likewise, this system significantly reduced the post- 
implant inflammation that normally occurs in the first days after 
administration [171]. 
Finally, in some cases, in order to avoid the need to remove the 
implant after treatment, biodegradable systems that can be eliminated 
when necessary could be the best option [199]. 
The field of synthetic biology has opened new perspectives for cell 
microencapsulation technologies. Using genetic engineering techniques, 
it is possible to reprogram the metabolic activities of eukaryotic cells so 
that they produce the therapeutic molecule at the right time. The 
secretion can be activated by a specific inducer or even in direct 
response to the needs of the patient [200–202] — when working with 
more advanced systems —, capable of interpreting and reacting to 
various pathophysiological stimuli [203,204]. Taking control over the 
therapeutic molecule expression levels allows us to administer the 
necessary dose, increasing the efficacy and minimizing adverse events. 
Finally, when these functionalities are incorporated into encapsu-
lated cells, an adequate control over the system is mandatory, avoiding 
possible genetic construct-transfers to the host’s cells or checking that 
these systems do not interfere with the metabolic processes of the host. 
4. Concluding remarks and future prospects 
The clinical application of cell microencapsulation technologies has 
remained elusive for decades, even if the first clinical trials took place 
more than 20 years ago [205]. One of the most limiting factors slowing 
the development of these systems is the great variability between the 
protocols used in different research groups. This, together with the lack 
of detail in the descriptions of the materials and processes used, makes 
the comparison between systems and the extraction of solid conclusions 
very complicated. Despite promising preclinical results and decades of 
technology development, phase I/II clinical trials performed to date 
resulted in poor outcomes, with fibrotic reaction being the major factor 
responsible for graft failure [32,205–209]. Thus, combating the foreign 
body reaction is crucial for improving implant outcomes, along with 
ensuring an appropriate supply of nutrients and oxygen to the encap-
sulated cells. 
In recent years, the improvements made in the alginate — either by 
optimized purification protocols [19–22] or the recent proposals to 
modify its chemical structure [28] — and the emergence of stem cell 
therapies, have greatly improved key biocompatibility issues, taking the 
technology an step forward in terms of efficacy. 
Finally, as previously discussed, the shape and size of the implant 
[158], which is still a controversial topic [27], or the administration 
route, are also other factors influencing the outcome of graft viability. In 
this regard, the optimal site should be accessible via minimally invasive 
methods, ensure a good vascularization of the implant, and not elicit a 
strong immune reaction. 
In the upcoming years, cell microencapsulation technologies are 
expected to finally reach the market, but their success will mainly 
depend on their ability to meet the strict regulations applied to cellular 
therapies and the possibility to set up large-scale practices that allow the 
safe and efficient production of the microcapsule batches. Even if there 
are still some aspects that need to be optimized, the extensive work 
carried out to date, in terms of improving key aspects such as efficacy 
and biosafety, have taken cell microencapsulation technologies closer 
than ever to the clinical practice. 
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Fig. 8. Monitoring implantable immunoisolation devises with intrinsic 
fluorescence of genipin. A Representative epifluorescence micrograph. B 
Representative confocal fluorescence image of cells encapsulated in genipin- 
cross-linked double poly-L-Lysine membrane (GDP) microcapsules and probed 
with LIVE/DEAD viability kit (Green, living cells; Red, dead cells) 14 days after 
encapsulation. C Representative image of a mouse 21 days after injection of 
GDP microcapsules. The fluorescence from the microcapsules was imaged with 
570 nm excitation and 620 nm emission. Scale bar denotes range of photons 
displayed on a pseudocolor scale with yellow and dark red denoting highest and 
lowest values, respectively. D Graph displays dose-dependent response of 
average radiant efficiency for GDP microcapsules. Reprinted from ref. [188], 
Copyright 2018, with permission from John Wiley and Sons. 
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[201] V. Ortner, C. Kaspar, C. Halter, L. Töllner, O. Mykhaylyk, J. Walzer, H. Günzburg, 
J.A. Dangerfield, C. Hohenadl, T. Czerny, Magnetic field-controlled gene 
expression in encapsulated cells, J. Control. Release 158 (2012) 424–432. 
[202] H. Chang, P. Kim, H. Cho, S. Yum, Y. Choi, Y. Son, D. Lee, I. Kang, K. Kang, 
G. Jang, J. Cho, Inducible HGF-secreting Human Umbilical Cord Blood-derived 
MSCs Produced via TALEN-mediated Genome Editing Promoted Angiogenesis, 
Mol. Ther. 24 (2016) 1644–1654. 
[203] W. Weber, M. Fussenegger, Emerging biomedical applications of synthetic 
biology, Nat. Rev. Genet. 13 (2011) 21–35. 
[204] R.J. Gubeli, K. Burger, W. Weber, Synthetic biology for mammalian cell 
technology and materials sciences, Biotechnol. Adv. 31 (2013) 68–78. 
[205] P. Soon-Shiong, R.E. Heintz, N. Merideth, Q.X. Yao, Z. Yao, T. Zheng, M. Murphy, 
M.K. Moloney, M. Schmehl, M. Harris, Insulin independence in a type 1 diabetic 
patient after encapsulated islet transplantation, Lancet. 343 (1994) 950–951. 
[206] C. Hasse, G. Klock, A. Schlosser, U. Zimmermann, M. Rothmund, Parathyroid 
allotransplantation without immunosuppression, Lancet. 350 (1997) 1296–1297. 
[207] R. Calafiore, G. Basta, G. Luca, A. Lemmi, M.P. Montanucci, G. Calabrese, 
L. Racanicchi, F. Mancuso, P. Brunetti, Microencapsulated pancreatic islet 
allografts into nonimmunosuppressed patients with type 1 diabetes: first two 
cases, Diabetes Care 29 (2006) 137–138. 
[208] R.B. Elliott, L. Escobar, P.L. Tan, M. Muzina, S. Zwain, C. Buchanan, Live 
encapsulated porcine islets from a type 1 diabetic patient 9.5 yr after 
xenotransplantation, Xenotransplantation 14 (2007) 157–161. 
[209] B.E. Tuch, G.W. Keogh, L.J. Williams, W. Wu, J.L. Foster, V. Vaithilingam, 
R. Philips, Safety and viability of microencapsulated human islets transplanted 
into diabetic humans, Diabetes Care 32 (2009) 1887–1889. 
T.B. Lopez-Mendez et al.                                                                                                                                                                                                                      
